home / stock / meip / meip quote
Last: | $2.86 |
---|---|
Change Percent: | 1.72% |
Open: | $2.8501 |
Close: | $2.86 |
High: | $2.95 |
Low: | $2.8226 |
Volume: | 18,961 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.86 | $2.8501 | $2.86 | $2.95 | $2.8226 | 18,961 | 05-31-2024 |
$2.9 | $2.9247 | $2.9 | $2.955 | $2.9 | 14,837 | 05-30-2024 |
$2.92 | $3.02 | $2.92 | $3.07 | $2.8868 | 34,865 | 05-29-2024 |
$3.0657 | $3.1 | $3.0657 | $3.125 | $3.0657 | 5,017 | 05-28-2024 |
$3.1 | $3.19 | $3.1 | $3.19 | $3.06 | 12,399 | 05-27-2024 |
$3.1 | $3.19 | $3.1 | $3.19 | $3.06 | 12,399 | 05-24-2024 |
$3.135 | $3.2 | $3.135 | $3.2 | $3.135 | 7,830 | 05-23-2024 |
$3.1899 | $3.11 | $3.1899 | $3.1976 | $3.1 | 38,646 | 05-22-2024 |
$3.12 | $3.16 | $3.12 | $3.16 | $3.11 | 5,028 | 05-21-2024 |
$3.11 | $3.14 | $3.11 | $3.1411 | $3.1 | 7,414 | 05-20-2024 |
$3.15 | $2.96 | $3.15 | $3.18 | $2.96 | 13,284 | 05-17-2024 |
$2.93 | $3.08 | $2.93 | $3.3117 | $2.87 | 61,823 | 05-16-2024 |
$3.105 | $3.16 | $3.105 | $3.24 | $3.07 | 29,026 | 05-15-2024 |
$3.16 | $3.11 | $3.16 | $3.24 | $3.08 | 14,847 | 05-14-2024 |
$3.12 | $3 | $3.12 | $3.12 | $3 | 9,987 | 05-13-2024 |
$3.02 | $3.07 | $3.02 | $3.07 | $3.01 | 8,473 | 05-10-2024 |
$3.07 | $3.09 | $3.07 | $3.1453 | $3.07 | 14,114 | 05-09-2024 |
$3.16 | $3.06 | $3.16 | $3.21 | $3.06 | 2,593 | 05-08-2024 |
$3.13 | $3.2 | $3.13 | $3.2 | $2.99 | 25,158 | 05-07-2024 |
$3.2 | $3.06 | $3.2 | $3.3 | $3.06 | 15,179 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...